NewsBenzinga파시테아의 PAS-004, 평가 가능한 15명 참가자 전원에서 피부 신경섬유종 감소···중간값 기준 최대 41% 감소, 2상 예정 용량에서 46% 감소, 치료 관련 중증 이상반응 없어 파시테아의 PAS-004, 평가 가능한 15명 참가자 전원에서 피부 신경섬유종 감소···중간값 기준 최대 41% 감소, 2상 예정 용량에서 46% 감소, 치료 관련 중증 이상반응 없어 Benzinga 2026.11.13 07:21 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory